These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 20920984

  • 1. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.
    Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT.
    Clin Breast Cancer; 2010 Oct 01; 10(5):392-7. PubMed ID: 20920984
    [Abstract] [Full Text] [Related]

  • 2. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
    Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K.
    Breast Cancer Res Treat; 2010 Nov 01; 124(2):403-12. PubMed ID: 20859679
    [Abstract] [Full Text] [Related]

  • 3. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.
    Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, Biganzoli L, Giannini A, Di Leo A.
    Breast Cancer Res Treat; 2009 Dec 01; 118(3):523-30. PubMed ID: 19597704
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, Brandt B.
    Clin Cancer Res; 2006 Mar 15; 12(6):1715-20. PubMed ID: 16551854
    [Abstract] [Full Text] [Related]

  • 6. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
    Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE.
    Ann Surg Oncol; 2007 Dec 15; 14(12):3359-68. PubMed ID: 17906897
    [Abstract] [Full Text] [Related]

  • 7. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
    Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM.
    Breast Cancer Res Treat; 2011 Sep 15; 129(2):451-8. PubMed ID: 21710134
    [Abstract] [Full Text] [Related]

  • 8. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
    Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, Friedrich MG, Shariat SF, Fisch M, Pantel K, Riethdorf S.
    Eur Urol; 2012 Apr 15; 61(4):810-7. PubMed ID: 22277196
    [Abstract] [Full Text] [Related]

  • 9. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M, Hartkopf AD, Riethdorf S, Nees J, Sprick MR, Schönfisch B, Taran FA, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A.
    BMC Cancer; 2015 May 14; 15():403. PubMed ID: 25972110
    [Abstract] [Full Text] [Related]

  • 10. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
    Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V.
    Breast Cancer Res; 2006 May 14; 8(4):R36. PubMed ID: 16846533
    [Abstract] [Full Text] [Related]

  • 11. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
    Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D.
    Breast Cancer Res Treat; 2009 Oct 14; 117(3):525-34. PubMed ID: 19016323
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
    Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, Brouwer A, de Jongh FE, Jager A, Seynaeve CM, Van NM, Foekens JA, Martens JW, Sleijfer S.
    Neoplasia; 2016 Nov 14; 18(11):647-653. PubMed ID: 27764697
    [Abstract] [Full Text] [Related]

  • 14. Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients.
    Tokudome N, Ito Y, Takahashi S, Kobayashi K, Taira S, Tsutsumi C, Oto M, Oba M, Inoue K, Kuwayama A, Masumura K, Nakayama Y, Watanabe C, Hatake K.
    Breast Cancer; 2011 Jul 14; 18(3):195-202. PubMed ID: 21465230
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer.
    Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, Suzuki E.
    Breast Cancer; 2010 Jul 14; 17(3):199-204. PubMed ID: 19649686
    [Abstract] [Full Text] [Related]

  • 17. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
    Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN.
    Breast Cancer Res Treat; 2013 Jan 14; 137(2):503-10. PubMed ID: 23271327
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M, DETECT Study Group.
    BMC Cancer; 2016 Jul 25; 16():522. PubMed ID: 27456970
    [Abstract] [Full Text] [Related]

  • 19. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.
    Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V.
    Breast Cancer Res; 2015 Aug 19; 17(1):113. PubMed ID: 26285572
    [Abstract] [Full Text] [Related]

  • 20. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.
    Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramírez-Moreno R, van Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, Martens JW.
    Clin Cancer Res; 2011 Jun 01; 17(11):3600-18. PubMed ID: 21505063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.